New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

In this MEDtalk from the World Conference on Lung Cancer (WCLC), Dr. Pasi A. Jänne, MD, PhD, Senior Vice President of Translational Medicine at Dana-Farber Cancer Institute, presents promising phase 1 results for the PRMT5 inhibitor BMS-986504 in MTAP-deleted non-small cell lung cancer. The agent shows durable responses and good tolerability, including in patients with EGFR and ALK-positive tumors who have received prior targeted therapies.